Information Provided By: 
Fly News Breaks for July 17, 2017
CRME
Jul 17, 2017 | 07:35 EDT
Canaccord analyst Dewey Steadman assumed coverage on Cardiome with a Buy rating as he sees an attractive top-line growth story driven by a unique business model commercializing hospital-based assets outside the U.S. market. The analyst sees additional upside driven by potential future business development and progress on commercialization of Brinavess. Steadman has an $8 price target on Cardiome shares.
News For CRME From the Last 2 Days
There are no results for your query CRME
